Here we address concurrent targeted therapeutic strategies directed toward immune suppression driven by PD-L1 modulation by the PI3K pathway, which is a key mechanism of resistance to existing therapies in PTCL progression. Here, CD274 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.